An internal standard for the quantification of 6-ECDCA
Related Products
Unlabeled Version(s)
110316-ECDCA
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

6-ECDCA-d4

Item No. 39007

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(3α,5β,6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic-2,2,4,4-d4 acid
CAS Number
2025364-15-0
Synonyms
  • 6α-ethyl Chenodeoxycholic Acid-d4
  • Obeticholic Acid-d4
Molecular Formula
C26H40D4O4
Formula Weight
424.7
Purity
≥99% deuterated forms (d1-d4)
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Sparingly soluble: 1-10 mg/ml
SMILES
O[C@@H]1C([2H])([2H])C[C@@]2(C)[C@@]([C@@H](CC)[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@@H](CCC(O)=O)C)([H])C1([2H])[2H]
InChi Code
InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1/i10D2,14D2
InChi Key
ZXERDUOLZKYMJM-LMUSDRRCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $50

    Add

    5 mg

    $186

    Add

    10 mg

    $323

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    6-ECDCA-d4 is intended for use as an internal standard for the quantification of 6-ECDCA (Item No. 11031) by GC- or LC-MS. 6-ECDCA is a synthetic bile acid that acts as a potent and selective agonist of the farnesoid X receptor (FXR; EC50 = 99 nM).1 Through FXR, it alters gene expression that results in protection against cholestasis, as well as liver fibrosis, in animal models.1,2,3 6-ECDCA also, through FXR, promotes the differentiation of adipocytes and enhances insulin signaling in mature adipocytes.4 In ApoE-/- mice, 6-ECDCA ameliorates vascular calcification secondary to chronic kidney disease without affecting the development of atherosclerosis.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Pellicciari, R., Fiorucci, S., Camaioni, E., et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45(17), 3569-3572 (2002).

    2. Fiorucci, S., Clerici, C., Antonelli, E., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313(2), 604-612 (2005).

    3. Fiorucci, S., Rizzo, G., Antonelli, E., et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314(2), 584-595 (2005).

    4. Rizzo, G., Disante, M., Mencarelli, A., et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 70(4), 1164-1173 (2006).

    5. Miyazaki-Anzai, S., Levi, M., Kratzer, A., et al. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ. Res. 106(12), 1807-1817 (2010).